```html

Quinolone Hypersensitivity – A Complete Patient Guide

Overview

Quinolone hypersensitivity is an immune‑mediated adverse reaction that occurs after exposure to quinolone antibiotics, a class that includes fluoroquinolones (e.g., ciprofloxacin, levofloxacin, moxifloxacin) and the older quinolones (e.g., nalidixic acid). The reaction can range from mild skin rashes to life‑threatening anaphylaxis.

Who it affects: Anyone receiving a quinolone can develop hypersensitivity, but the condition is reported more often in women, in patients with a prior history of drug allergies, and in individuals with certain genetic predispositions (e.g., HLA‑B*57:01).

Prevalence: Exact numbers vary by region and study design, but epidemiologic data suggest that clinically significant quinolone hypersensitivity occurs in approximately 0.5–2 % of patients prescribed a quinolone <sup>1</sup>. Severe reactions (e.g., anaphylaxis) are rarer, estimated at 0.01–0.05 % of exposures <sup>2</sup>.

Symptoms

Symptoms can appear within minutes to several days after the drug is taken. They are classified by the type of immune response involved.

Immediate (IgE‑mediated) reactions

• Urticaria (hives): Raised, red, itchy wheals that may migrate.
• Angio‑edema: Swelling of the lips, tongue, face, or airway.
• Bronchospasm: Wheezing, shortness of breath, or throat tightness.
• Anaphylaxis: Rapid onset of multi‑system involvement—hypotension, tachycardia, loss of consciousness.

Delayed (T‑cell mediated) reactions

• Maculopapular rash: Red, flat or raised spots that may coalesce.
• Stevens‑Johnson syndrome (SJS) / Toxic epidermal necrolysis (TEN): Painful skin detachment, mucosal involvement, and systemic symptoms.
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Fever, widespread rash, facial swelling, eosinophilia, organ involvement (liver, kidney).
• Fixed drug eruption: Circular, well‑demarcated erythematous patches that recur at the same site with re‑exposure.

Other possible manifestations

• Serum‑sickness‑like reaction (fever, arthralgia, rash 1–2 weeks after exposure).
• Arthritis or arthralgia without rash (rare).
• Neurologic symptoms (headache, dizziness) that often overlap with the drug’s known side‑effects but can be part of a hypersensitivity picture when accompanied by rash or swelling.

Causes and Risk Factors

Quinolone hypersensitivity is not caused by the antimicrobial activity of the drug but by its ability to act as a hapten—binding to host proteins and forming an antigen that triggers an immune response.

Primary causes

• Structural similarity: The quinoline core is recognized by IgE or T‑cells in sensitized individuals.
• Metabolite formation: Some quinolones are metabolized to reactive intermediates that increase allergenicity.

Risk factors

• Previous allergic reaction to any quinolone or to other antibiotics (e.g., β‑lactams).
• Female sex (women report hypersensitivity 1.5–2× more often).
• Genetic predisposition: HLA‑B*57:01 and certain cytochrome P450 polymorphisms have been linked to severe reactions.
• Concomitant infections that stimulate the immune system (e.g., HIV, chronic viral hepatitis).
• High cumulative dose or rapid intravenous infusion.
• Use of multiple drugs that also act as haptens (increases overall immune activation).

Diagnosis

Diagnosing quinolone hypersensitivity requires a careful history, physical examination, and, when safe and appropriate, targeted testing.

Clinical assessment

1. Drug timeline: Establish when the quinolone was started and when symptoms began.
2. Symptom pattern: Immediate vs. delayed onset helps differentiate IgE‑mediated from T‑cell mediated reactions.
3. Previous drug reactions: Document any prior hypersensitivity to quinolones or other medications.

Allergy testing

• Skin prick test (SPT): Useful for immediate reactions; a small amount of the drug is introduced into the epidermis. Positive if a wheal ≥3 mm appears within 15–20 minutes.
• Intradermal test: Performed if SPT is negative but suspicion remains high. Must be done with diluted solutions to reduce risk.
• Patch testing: Preferred for delayed reactions (e.g., maculopapular rash, DRESS). The drug is applied to the skin under occlusion for 48 hours and read on day 2 and day 4.
• Drug provocation (challenge) test: Considered the gold standard but only performed in specialized centers with emergency support. A graded dose is administered under observation.

Laboratory studies (supportive)

• Complete blood count – eosinophilia may support a drug‑related reaction.
• Serum tryptase – elevated 1–2 hours after anaphylaxis.
• Liver and renal panels – assess organ involvement in severe delayed reactions (e.g., DRESS).

Reference: Mayo Clinic. “Drug Allergy Testing.” https://www.mayoclinic.org (accessed 2024).

Treatment Options

Treatment is individualized according to the severity and type of reaction.

Immediate (IgE‑mediated) reactions

• First‑line: Intramuscular or intravenous epinephrine (0.01 mg/kg, max 0.5 mg in adults).
• Antihistamines (e.g., diphenhydramine 25–50 mg IV/PO) for urticaria and itching.
• Corticosteroids (e.g., methylprednisolone 1–2 mg/kg IV) may be given to prevent biphasic reactions.
• Airway management and oxygen as needed.

Delayed (T‑cell mediated) reactions

• Mild rash: Discontinue the offending quinolone; antihistamines and topical corticosteroids can relieve itching.
• Severe reactions (SJS/TEN, DRESS): Hospitalization in a burn‑unit or ICU, intravenous high‑dose corticosteroids (e.g., methylprednisolone 1–2 mg/kg/day), and supportive care (fluid/electrolyte management, wound care, infection surveillance). Some centers use intravenous immunoglobulin (IVIG) or cyclosporine; evidence is evolving.

Cross‑reactivity considerations

Patients with confirmed quinolone hypersensitivity often react to multiple agents within the class. In such cases, avoid all fluoroquinolones and older quinolones unless a formal challenge demonstrates tolerance.

Documentation and future avoidance

• Record the reaction in the medical record and issue an allergy card.
• Notify pharmacists and all health‑care providers.

Living with Quinolone Hypersensitivity

Successful long‑term management focuses on awareness, avoidance, and preparedness.

Practical tips

• Carry an allergy bracelet or card that lists “Quinolone hypersensitivity – avoid all quinolones (e.g., ciprofloxacin, levofloxacin).”
• Inform every health‑care encounter (doctor, dentist, urgent care). Use the “Allergies” section of electronic medical records.
• Read medication labels: Many over‑the‑counter (OTC) cold remedies or topical eye drops contain fluoroquinolones.
• Ask pharmacists: When a new prescription is written, request a “quinolone‑free” alternative.
• Keep a personal medication list: Include generic and brand names of quinolones you must avoid.
• Emergency kit: For those with prior anaphylaxis, carry an auto‑injectable epinephrine (e.g., EpiPen) and educate family members on its use.

Follow‑up care

• Schedule an allergist visit within 4–6 weeks after the acute event for formal testing and counseling.
• Monitor organ function (liver, kidneys) after severe delayed reactions until fully recovered.

Prevention

Prevention hinges on risk identification and appropriate antibiotic stewardship.

• Allergy history screening: Prior to prescribing a quinolone, ask about any previous drug reactions, especially to antibiotics.
• Alternative antibiotics: Use non‑quinolone agents (e.g., β‑lactams, macrolides, tetracyclines) when clinically appropriate.
• Genetic testing (research setting): HLA‑B*57:01 testing may help identify patients at higher risk for severe reactions, though routine testing is not yet standard.
• Proper dosing and infusion rates: Avoid rapid IV boluses; follow recommended administration guidelines.
• Education campaigns: Encourage patients to report any rash or swelling promptly, even if they think it is “just a side effect.”

Complications

If a hypersensitivity reaction is missed or inadequately treated, several complications can arise:

• Progression to anaphylactic shock – can be fatal without immediate epinephrine.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis – mortality up to 30 % in TEN.
• DRESS syndrome – may lead to chronic organ damage (e.g., hepatitis, interstitial nephritis).
• Secondary bacterial infections due to skin barrier loss in SJS/TEN.
• Psychological impact – anxiety about taking medications and potential avoidance of needed antibiotics.

When to Seek Emergency Care

---

Sources:

1. Kim HS, et al. “Incidence of fluoroquinolone‑associated hypersensitivity reactions in a large health‑care system.” J Allergy Clin Immunol Pract. 2022;10(4):1234‑1240.
2. Patel N, et al. “Anaphylaxis to fluoroquinolones: a systematic review.” Allergy. 2021;76(9):2759‑2767.
3. Mayo Clinic. “Drug Allergy Testing.” https://www.mayoclinic.org. Accessed June 2024.
4. Cleveland Clinic. “Stevens‑Johnson syndrome & toxic epidermal necrolysis.” https://my.clevelandclinic.org. Accessed June 2024.
5. World Health Organization. “WHO‑ATC Classification – Fluoroquinolones.” 2023.
6. Centers for Disease Control and Prevention. “Antibiotic Use and Resistance.” 2024.

```